ZEPP
ZEPP
Zepp Health CorporationIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $539.56M ▲ | $212.2M ▲ | $-11.5M ▲ | -2.13% ▲ | $-0.73 ▲ | $6.44M ▲ |
| Q2-2025 | $427.07M ▲ | $198.35M ▼ | $-55.64M ▲ | -13.03% ▲ | $-3.5 ▲ | $-36.2M ▲ |
| Q1-2025 | $279.89M ▼ | $237.76M ▲ | $-143.37M ▲ | -51.23% ▲ | $-9.32 ▲ | $-130.11M ▲ |
| Q4-2024 | $433.03M ▲ | $224.49M ▲ | $-268.55M ▼ | -62.02% ▼ | $-16.74 ▼ | $-134.28M ▼ |
| Q3-2024 | $297.67M | $208.77M | $-92.89M | -31.21% | $-5.76 | $-80.65M |
What's going well?
Sales jumped 26% and losses shrank sharply, showing the company can scale up and control costs. Gross margins improved, and efficiency is trending better as expenses grow slower than revenue.
What's concerning?
The company is still losing money and interest costs are rising. Overhead costs are up, and profitability remains out of reach for now.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $446.69M ▼ | $4.17B ▲ | $2.56B ▲ | $1.61B ▼ |
| Q2-2025 | $690.15M ▼ | $3.93B ▲ | $2.32B ▲ | $1.61B ▼ |
| Q1-2025 | $761.42M ▼ | $3.77B ▼ | $2.08B ▲ | $1.69B ▼ |
| Q4-2024 | $815.51M ▼ | $3.86B ▼ | $2.01B ▲ | $1.84B ▼ |
| Q3-2024 | $929.8M | $4.13B | $1.92B | $2.2B |
What's financially strong about this company?
Debt was paid down significantly this quarter, and the company still has over $1 billion in liquid assets. Most assets are tangible, and equity is solidly positive.
What are the financial risks or weaknesses?
Cash reserves fell sharply, and the company is delaying payments to suppliers, which could signal cash flow stress. Retained earnings are negative, showing little historical profit.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.5M ▲ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q2-2025 | $-55.64M ▲ | $0 | $0 | $0 | $-61M ▼ | $0 |
| Q1-2025 | $-143.37M ▲ | $0 | $0 | $0 | $-50.1M ▼ | $0 |
| Q4-2024 | $-269.16M ▼ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q3-2024 | $-92.89M | $0 | $0 | $0 | $-6.53M | $0 |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Zepp Health Corporation's financial evolution and strategic trajectory over the past five years.
Zepp’s core strengths include its vertically integrated technology stack, differentiated focus on long battery life and AI-driven health insights, and a growing ecosystem that now spans smartwatches, fitness wearables, hearing aids, and wellness services. Historically, it has demonstrated the ability to earn solid gross profits and to generate strong cash flow in more favorable years. The balance sheet still shows positive equity and a meaningful asset base, which provides some buffer as the company works through a difficult period.
The main risks are financial and competitive. Revenue has fallen sharply, losses have deepened, and cash flows have turned mostly negative, while liquidity has weakened and net debt has risen. If these trends persist, they could constrain the company’s ability to invest sufficiently in R&D, marketing, and ecosystem expansion, just as competition in wearables and digital health remains fierce. There is also execution risk around new product categories and AI features—if these do not gain traction, the payoff from current innovation efforts may be limited.
The outlook is highly dependent on Zepp’s ability to stabilize its top line and restore at least break-even economics while preserving enough R&D and marketing firepower to maintain differentiation. Its technology platform and ecosystem give it tools to pursue a turnaround, especially if it can deepen engagement with health-focused users and carve out defensible niches. At the same time, the current financial trajectory is unfavorable, leaving the near- to medium-term picture cautious and uncertain until clearer evidence of revenue stabilization, margin improvement, and more consistent positive cash generation emerges.
About Zepp Health Corporation
https://www.huami.comZepp Health Corporation, together with its subsidiaries, develops, manufactures, and sells smart wearable technological devices in the People's Republic of China. It operates through two segments, Xiaomi Wearable Products, and Self-Branded Products and Others.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $539.56M ▲ | $212.2M ▲ | $-11.5M ▲ | -2.13% ▲ | $-0.73 ▲ | $6.44M ▲ |
| Q2-2025 | $427.07M ▲ | $198.35M ▼ | $-55.64M ▲ | -13.03% ▲ | $-3.5 ▲ | $-36.2M ▲ |
| Q1-2025 | $279.89M ▼ | $237.76M ▲ | $-143.37M ▲ | -51.23% ▲ | $-9.32 ▲ | $-130.11M ▲ |
| Q4-2024 | $433.03M ▲ | $224.49M ▲ | $-268.55M ▼ | -62.02% ▼ | $-16.74 ▼ | $-134.28M ▼ |
| Q3-2024 | $297.67M | $208.77M | $-92.89M | -31.21% | $-5.76 | $-80.65M |
What's going well?
Sales jumped 26% and losses shrank sharply, showing the company can scale up and control costs. Gross margins improved, and efficiency is trending better as expenses grow slower than revenue.
What's concerning?
The company is still losing money and interest costs are rising. Overhead costs are up, and profitability remains out of reach for now.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $446.69M ▼ | $4.17B ▲ | $2.56B ▲ | $1.61B ▼ |
| Q2-2025 | $690.15M ▼ | $3.93B ▲ | $2.32B ▲ | $1.61B ▼ |
| Q1-2025 | $761.42M ▼ | $3.77B ▼ | $2.08B ▲ | $1.69B ▼ |
| Q4-2024 | $815.51M ▼ | $3.86B ▼ | $2.01B ▲ | $1.84B ▼ |
| Q3-2024 | $929.8M | $4.13B | $1.92B | $2.2B |
What's financially strong about this company?
Debt was paid down significantly this quarter, and the company still has over $1 billion in liquid assets. Most assets are tangible, and equity is solidly positive.
What are the financial risks or weaknesses?
Cash reserves fell sharply, and the company is delaying payments to suppliers, which could signal cash flow stress. Retained earnings are negative, showing little historical profit.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.5M ▲ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q2-2025 | $-55.64M ▲ | $0 | $0 | $0 | $-61M ▼ | $0 |
| Q1-2025 | $-143.37M ▲ | $0 | $0 | $0 | $-50.1M ▼ | $0 |
| Q4-2024 | $-269.16M ▼ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q3-2024 | $-92.89M | $0 | $0 | $0 | $-6.53M | $0 |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Zepp Health Corporation's financial evolution and strategic trajectory over the past five years.
Zepp’s core strengths include its vertically integrated technology stack, differentiated focus on long battery life and AI-driven health insights, and a growing ecosystem that now spans smartwatches, fitness wearables, hearing aids, and wellness services. Historically, it has demonstrated the ability to earn solid gross profits and to generate strong cash flow in more favorable years. The balance sheet still shows positive equity and a meaningful asset base, which provides some buffer as the company works through a difficult period.
The main risks are financial and competitive. Revenue has fallen sharply, losses have deepened, and cash flows have turned mostly negative, while liquidity has weakened and net debt has risen. If these trends persist, they could constrain the company’s ability to invest sufficiently in R&D, marketing, and ecosystem expansion, just as competition in wearables and digital health remains fierce. There is also execution risk around new product categories and AI features—if these do not gain traction, the payoff from current innovation efforts may be limited.
The outlook is highly dependent on Zepp’s ability to stabilize its top line and restore at least break-even economics while preserving enough R&D and marketing firepower to maintain differentiation. Its technology platform and ecosystem give it tools to pursue a turnaround, especially if it can deepen engagement with health-focused users and carve out defensible niches. At the same time, the current financial trajectory is unfavorable, leaving the near- to medium-term picture cautious and uncertain until clearer evidence of revenue stabilization, margin improvement, and more consistent positive cash generation emerges.

CEO
Wang Huang
Compensation Summary
(Year )
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-09-16 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
FIL LTD
Shares:625.76K
Value:$12.06M
MORGAN STANLEY
Shares:610.29K
Value:$11.77M
POINT72 ASSET MANAGEMENT, L.P.
Shares:577.97K
Value:$11.14M
Summary
Showing Top 3 of 51

